PMID- 33202794
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20230919
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 22
DP  - 2020 Nov 13
TI  - Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
LID - 10.3390/ijms21228553 [doi]
LID - 8553
AB  - The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell 
      (DLBCL). There is a historical unmet need for more effective therapies in the 2nd 
      and 3rd line setting. Emerging immunochemotherapies have shown activity in small 
      studies of heavily pre-treated patients with prolonged remissions achieved in 
      some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially 
      curative in the 3rd line and beyond setting and are under investigation in 
      earlier lines of therapy. Antibody-drug conjugates (ADC's) such as polatuzumab 
      vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in 
      multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal 
      antibody producing prolonged remissions when combined with Lenalidomide (LEN) in 
      patients who were not candidates for salvage chemotherapy or autologous stem cell 
      transplant. Selinexor, an oral, small-molecule selective inhibitor of 
      XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against 
      heavily-pretreated DLBCL without cumulative toxicity and is being investigated as 
      part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This 
      article reviews current strategies and novel therapies for relapsed/refractory 
      DLBCL.
FAU - Harris, Leonard Jeff
AU  - Harris LJ
AUID- ORCID: 0000-0002-4967-4618
AD  - Oncology Division, Department of Medicine, University of Tennessee Health 
      Sciences Center, Memphis, TN 38103, USA.
FAU - Patel, Kruti
AU  - Patel K
AUID- ORCID: 0000-0002-6527-5916
AD  - Oncology Division, Department of Medicine, University of Tennessee Health 
      Sciences Center, Memphis, TN 38103, USA.
FAU - Martin, Michael
AU  - Martin M
AD  - West Cancer Center & Research Institute, Memphis, TN 38103, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201113
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Hydrazines)
RN  - 0 (Immunoconjugates)
RN  - 0 (Triazoles)
RN  - 31TZ62FO8F (selinexor)
RN  - F0P408N6V4 (Lenalidomide)
RN  - KG6VO684Z6 (polatuzumab vedotin)
RN  - QQA9MLH692 (tafasitamab)
SB  - IM
MH  - *Adoptive Transfer
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Humans
MH  - Hydrazines/therapeutic use
MH  - Immunoconjugates/therapeutic use
MH  - Lenalidomide/therapeutic use
MH  - Lymphoma, Large B-Cell, Diffuse/metabolism/pathology/*therapy
MH  - Triazoles/therapeutic use
PMC - PMC7698117
OTO - NOTNLM
OT  - DLBLC
OT  - Relapsed or Refractory Diffuse Large B Cell Lymphoma
OT  - chemotherapy-free regimen
OT  - immunotherapy
COIS- The authors declare no conflict of interest.
EDAT- 2020/11/19 06:00
MHDA- 2021/03/04 06:00
PMCR- 2020/11/01
CRDT- 2020/11/18 01:01
PHST- 2020/09/29 00:00 [received]
PHST- 2020/11/02 00:00 [revised]
PHST- 2020/11/10 00:00 [accepted]
PHST- 2020/11/18 01:01 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
PHST- 2020/11/01 00:00 [pmc-release]
AID - ijms21228553 [pii]
AID - ijms-21-08553 [pii]
AID - 10.3390/ijms21228553 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Nov 13;21(22):8553. doi: 10.3390/ijms21228553.